Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of atorvastatin plus temozolomide in primary glioblastoma with high EGFR pathway activity
ChiCTR2400081288Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Feb 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atorvastatin and temozolomide in glioblastoma (GBM), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Progression-free survival, Overall survival and 1 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
atorvastatintemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2400081288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081288.